Horizon Acquires Viela, Will Develop Inebilizumab for MG Symptoms
In a $3.05 billion deal, Horizon Therapeutics will acquire Viela Bio, the developer of inebilizumab, a potential treatment for autoimmune diseases such as myasthenia gravis (MG), the two companies announced. Horizon plans to advance inebilizumab, already approved for treating another rare autoimmune disease, as a therapy for decreasing disease…